HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
Clinical trial NCT05127226 · RECRUITING
Trial details
- NCT number
- NCT05127226
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-22
- Primary completion
- 2029-03-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.